T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients
- PMID: 29936407
- DOI: 10.1016/j.jcv.2018.06.009
T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients
Abstract
Background: Assays detecting CMV-specific cell-mediated immunity (CMI) may support the current management of CMV infection in solid-organ transplant (SOT) recipients, by allowing a better risk assessment and adjusting antiviral treatment.
Objectives: The primary endpoint was the performance of two tests measuring CMV-specific interferon-gamma production, both approved for commercial use in clinical settings. Secondarily, we determined a cut-off for the cellular immune response, which protects against CMV reactivation/infection.
Study design: Thirty kidney transplant (KTx) patients were stratified according to their CMV-IgG status pre-transplantation (Tx) and were divided into two groups: pre-emptive (donor-/recipient+, donor+/recipient+) and prophylaxis (donor+/recipient-). An ELISpot (T-Track-CMV) was performed at month 1 post-Tx (pre-emptive group) and end of prophylaxis and one month thereafter (prophylaxis group). An ELISA (QuantiFERON-CMV) was performed every 2-4 weeks (pre-emptive) or monthly (prophylaxis), in parallel to the CMV viral load (PCR).
Results: A good positive agreement was obtained between the QuantiFERON-CMV or T-Track-CMV and the CMV-IgG (kappa = 0.839 and 0.824, respectively). A cut-off of 19.5 spot forming units (SFU)/200,000 lymphocytes for the T-Track-CMV IE-1 (AUC = 0.802, sensitivity 45%, specificity 100%) and 495 SFU/200,000 lymphocytes for the T-Track-CMV pp65 (AUC = 0.617, sensitivity 11%, specificity 100%) was defined to assess protection against reactivation. The QuantiFERON-CMV performed modestly (AUC = 0.477, cut-off 85.1 IU/ml).
Conclusions: The QuantiFERON-CMV and T-Track-CMV enable the functional assessment of CMV-specific CMI in KTx recipients. In combination with CMV viral load monitoring, T-Track-CMV results could stratify patients at risk of CMV reactivation/infection.
Keywords: CMV; Cell-mediated immunity; ELISpot; Kidney transplant; QuantiFERON.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.J Clin Virol. 2018 Feb-Mar;99-100:61-66. doi: 10.1016/j.jcv.2018.01.002. Epub 2018 Jan 9. J Clin Virol. 2018. PMID: 29331844
-
Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.J Clin Microbiol. 2013 Aug;51(8):2501-7. doi: 10.1128/JCM.00563-13. Epub 2013 May 15. J Clin Microbiol. 2013. PMID: 23678073 Free PMC article.
-
Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.BMC Immunol. 2017 Mar 7;18(1):15. doi: 10.1186/s12865-017-0194-z. BMC Immunol. 2017. PMID: 28270092 Free PMC article.
-
Immune Monitoring for CMV in Transplantation.Curr Infect Dis Rep. 2018 Mar 14;20(4):4. doi: 10.1007/s11908-018-0610-4. Curr Infect Dis Rep. 2018. PMID: 29542023 Review.
-
Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update.Diagnostics (Basel). 2021 May 13;11(5):875. doi: 10.3390/diagnostics11050875. Diagnostics (Basel). 2021. PMID: 34068377 Free PMC article. Review.
Cited by
-
Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.Infect Dis Rep. 2024 Jan 18;16(1):65-82. doi: 10.3390/idr16010005. Infect Dis Rep. 2024. PMID: 38247977 Free PMC article. Review.
-
Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients.Viruses. 2023 Jul 21;15(7):1595. doi: 10.3390/v15071595. Viruses. 2023. PMID: 37515280 Free PMC article. Review.
-
Immune-checkpoint expression in antigen-presenting cells (APCs) of cytomegaloviruses infection after transplantation: as a diagnostic biomarker.Arch Microbiol. 2023 Jul 10;205(8):280. doi: 10.1007/s00203-023-03623-8. Arch Microbiol. 2023. PMID: 37430000 Review.
-
Torque teno virus viremia and QuantiFERON®-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients.Front Med (Lausanne). 2023 Jun 22;10:1180769. doi: 10.3389/fmed.2023.1180769. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37425298 Free PMC article.
-
Cytomegalovirus Immunity Assays Predict Viremia but not Replication Within the Lung Allograft.Transplant Direct. 2023 Jun 9;9(7):e1501. doi: 10.1097/TXD.0000000000001501. eCollection 2023 Jul. Transplant Direct. 2023. PMID: 37313314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
